AstraZeneca-Amgen Combo Hits Survival Goal in Lung Cancer Trial
AMGN sits 53% above its 52-week low of $269.77.
Summary
AstraZeneca's Imfinzi combined with Amgen's Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial. This is a major positive for Amgen's oncology franchise, as Imdelltra is a key growth asset. The result validates the combination strategy and could expand the drug's market opportunity. Amgen shares are likely to react favorably to this news, especially given recent pressure from the Novartis trial failure. Watch for detailed data presentation at an upcoming medical conference.
At the time of this announcement, AMGN was trading at $411.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $236.4B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.